
A booster makes for longer-lasting antibodies, even for those who have had COVID-19, new research shows.
A booster makes for longer-lasting antibodies, even for those who have had COVID-19, new research shows.
That information could help doctors ensure patients with COVID-19 who are at high risk of getting very ill receive aggressive treatment early on.
A clinical trial suggests that an eczema treatment you may have seen advertised on TV may also reduce the risk of death from COVID-19.
In response to the stresses of the COVID-19 pandemic, a trio of enterprising nurses at UVA Health developed a "resilience toolbox" to help care providers take a break during their often exhausting shifts.
Antibodies from Pfizer's vaccine rose more slowly and declined more quickly than those generated by Moderna's vaccine.
Our Patrick Jackson, MD, an infectious disease expert, is feeling very optimistic. Read why and learn about how the forthcoming drugs work.